DigitalGlobe (DGI) - FREE Research Report

Scott Walter S. who is EVP & Chief Technical Officer at DigitalGlobe sold 853 shares at $31.61 on Oct. 2, 2013. Following this transaction, the EVP & Chief Technical Officer owned 152,056 shares meaning that the stake was reduced by 0.56% with the 853 share transaction.

The shares most recently traded at $31.14, down $0.47, or 1.51% since the insider transaction. Historical insider transactions for DigitalGlobe go as follows:

  • 4-Week # shares sold: 120
  • 12-Week # shares sold: 20,202
  • 24-Week # shares sold: 22,062

The average volume for DigitalGlobe has been 561,100 shares per day over the past 30 days. DigitalGlobe has a market cap of $2.5 billion and is part of the industrial goods sector and aerospace/defense industry. Shares are up 34.57% year to date as of the close of trading on Wednesday.

DigitalGlobe, Inc. provides commercial earth imagery products and services in the Americas and internationally. The company operates in two segments, Defense and Intelligence, and Commercial. Currently there are 4 analysts that rate DigitalGlobe a buy, 1 analyst rates it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DGI - FREE

TheStreet Quant Ratings rates DigitalGlobe as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full DigitalGlobe Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Illumina Lights the Way for Biotechs

Illumina Lights the Way for Biotechs

European Pharma Companies Slip on MS Pricing Probe

Biogen Stock Climbs After Goldman Adds to its 'Conviction Buy' List

Pfizer's Poor Earnings Feed the Allergan Tie-Up Fire